REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus en-docrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis.

Singer, CF; Egle, D; Greil, R; Petru, E; Ohler, L; Balic, M; Tinchon, C; Pfeiler, G; Marhold, M; Brunner, C; Haider, K; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Uthman, S; Mraz, B; Bartsch, R.
ANN ONCOL. 2022; 33: S217-S217.
https://www.sciencedirect.com/science/article/pii/S0923753422005932?via%3Dihub